Immatics NVIMTX +0.40%60 3-Year ROIIC % is 617.48 as of Dec. 2025, which is 1311% above its 10-year median of 43.77. GuruFocus rates IMTX with a GF Score™ of 60/100 and a GF Value™ of $3.41 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,320 Biotechnology companies, Immatics NV ranks better than 91.52% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Immatics NV's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 617.48%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Immatics NV's 3-Year ROIIC % or its related term are showing as below:
IMTX's 3-Year ROIIC % is ranked better than 91.52% of 1320
companies
in the Biotechnology industry
Industry Median: -4.42
vs IMTX: 617.48
Immatics NV (NAS:IMTX) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Immatics NV 3-Year ROIIC % Related Terms
Immatics NV 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Immatics NV's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMTX vs MNKD, JBIO, AVLN: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Immatics NV's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immatics NV 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immatics NV's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Immatics NV's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Immatics NV (IMTX) has a 3-Year ROIIC % of 617.48 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Immatics NV and its competitors. This is 1311% above median its historical median of 43.77. According to the industry distribution chart, Immatics NV ranks #112 out of 1320 companies in the Biotechnology industry, placing it in the top 8.5%.
Is Immatics NV's 3-Year ROIIC % too high?
Immatics NV's current 3-Year ROIIC % of 617.48 is 1311% above median its 10-year median of 43.77. Based on the distribution chart, Immatics NV ranks #112 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immatics NV has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immatics NV's 3-Year ROIIC % compare to MNKD and JBIO?
According to the Biotechnology industry distribution chart, Immatics NV ranks #112 out of 1320 companies for 3-Year ROIIC %. This places Immatics NV in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Immatics NV and its competitors. Immatics NV's current 3-Year ROIIC % is 617.48, which is 1311% above median its own 10-year median of 43.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immatics NV stock overvalued right now?
Based on GuruFocus' analysis, Immatics NV (IMTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.41, compared to a current price of $9.99 — trading 193% above its estimated fair value. The current 3-Year ROIIC % is 617.48, which is 1311% above median its 10-year median of 43.77. Immatics NV's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Immatics NV (IMTX), the current 3-Year ROIIC % is 617.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immatics NV (IMTX) Overvalued in 2026?
Based on GuruFocus' analysis, Immatics NV stock appears to be overvalued.
The current stock price of $9.99 is trading 193% above its estimated GF Value™ of $3.41.
GuruFocus considers Immatics NV to be Significantly Overvalued.
Key valuation signals for IMTX:
3-Year ROIIC %: 617.48 (1311% above median its 10-year median of 43.77)
GF Value™: $3.41 vs. price of $9.99 (193% above fair value)
No single metric tells the full story. See the IMTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
60GF Score
Get the complete analysis for IMTX
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMTX has been successfully added to your 
